STAR IKONE: Der VOLLTREFFER zieht GERADE an...!!!
Seite 2 von 2 Neuester Beitrag: 12.04.05 23:35 | ||||
| Eröffnet am: | 23.04.02 18:16 | von: Star Ikone | Anzahl Beiträge: | 41 |
| Neuester Beitrag: | 12.04.05 23:35 | von: phillie222 | Leser gesamt: | 7.845 |
| Forum: | Börse | Leser heute: | 6 | |
| Bewertet mit: |  | |||
| Seite: < 1 | > | ||||
Threads immer hoch holst verstehe ich nicht.
Eine Aktie die vor langer Zeit mal im Gespraech war, kann man nicht mit heute
vergleichen.
Der Kaeufer koennte ja mittlerweile mit Verlust oder Gewinn verkauft haben.
z.B. Kauf der Aktie XYZ in 2000
Preis $1
fiel bis 0,40
heutiger Kurs $5
Woher wissen wir ob der Kaeufer die Aktie gehalten hat oder wann er verkaufte ?
Stox Dude
Ich mag es, Aktien über viele Jahre zu beobachten.
Gruss E.
AASTROM BIOSCIENCES INC - Nasdaq SmallCap Market: ASTM
Consolidated Real-time Market Quote*
| Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
| 1.43 |  0.52 (57.14) | 0.23 (19.17) | 0 (0) | 0 (0) | 19:57 |
Exchange Quote
| Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
| 1.20 | 0.29 (31.87) | 1.46 (3) | 1.47 (10) | 16:00 |
| Day Volume | Last Size | Open | High | Low |
| 9,536,485 | 3,000 | 0.92 | 1.32 | 0.85 |
| Latest Ticks | # of Trades | Avg Trade Size | VWAP | 52 Wk High |
| ==== | 5,651 | 1,688 | 1.0979 | 0.99 |
| 52 Wk Low | Prev Close | Avg Day Vol | ||
| 0.22 | 0.91 | 3,008,600 |
Tuesday June 10, 7:01 am ET
-- Alliance Brings Together Industry Leaders in Stem Cells and Orthopedic Medicine --
ANN ARBOR, Mich., and EDISON, N.J., June 10 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and Musculoskeletal Transplant Foundation (MTF) today announced a strategic alliance to jointly develop and commercialize innovative treatments for the regeneration of tissues such as bone and cartilage. The companies will initially focus on combining their respective technologies to establish a novel treatment approach for bone graft applications. This market is estimated at over 1.4 million procedures annually, including spinal fusions, non-union fractures, dental defects and facial bone repair, and is expected to exhibit progressive growth in the future.
ADVERTISEMENT
The partnership aligns an industry leader in stem cell therapies (Aastrom) with the leading provider of allograft, or donor-derived tissue, matrices (MTF) to form a coordinated business and clinical approach for new products and treatments needed in orthopedic medicine. Under the terms of the alliance, the companies will provide each other with rights to their respective technologies for treatments and products that are based on combinations of MTF's matrices and Aastrom's Tissue Repair Cells (TRCs). The companies will share in the development and clinical trial expense of these treatment approaches and products, and will adopt a coordinated promotion and marketing strategy for future products. In addition to allograft-based bone graft treatments, the companies will explore new approaches for the regeneration of joint cartilage, as well as effective combinations of TRCs with MTF's new ceramic matrix technology.
"This strategic alliance gives Aastrom the partner we have been seeking in the orthopedic field, and will allow us to combine our capabilities and resources to jointly develop and then market an effective alternative to the current standard bone graft procedures," said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. "MTF is the world's largest and most respected allograft matrix provider, and its decision to partner with Aastrom validates our strategic position and focus on the commercial development of our bone and cartilage regeneration programs. This alliance, supported by MTF's technology, expertise and funding, should enable us to bring our technology through the regulatory and logistics pipeline and into the marketplace in the near term."
"We are very excited to be working with Aastrom in the area of stem cell technology. We believe that the combination of bone progenitor cells with the native architecture and compatibility provided by allograft tissues will produce a superior graft equal to the 'gold standard' of the patient's own tissues," said Bruce W. Stroever, President and Chief Executive Officer of MTF. "We believe this alliance brings together the business and technology components needed to pioneer the next era in orthopedic medicine, and maximize the beneficial use of the precious resource of donated tissue."
Aastrom has developed a powerful technology capable of producing a stem cell-based cell mixture from a small sample of the patient's own cells. These cells -- called Tissue Repair Cells -- have been shown in clinical trials to generate normal human tissues safely and reliably in patients. The Company has demonstrated in laboratory research that its TRCs contain more than a 70- fold increase in the number of bone-forming cell types, compared with the patient's own bone marrow.
Traditional bone grafting procedures, which use autograft, require the collection of bone and marrow by removing bone chips from a patient's own hip, an invasive surgical process resulting in acute and chronic pain, as well as long-term complications. In an attempt to eliminate this undesirable procedure, MTF has developed various forms of bone matrices from donated tissues. The companies believe that combining these matrices with Aastrom's TRCs will bring together all the components needed to regenerate bone similarly to autograft, and will eliminate the undesirable and painful surgical procedure currently needed to provide the autograft.
About Aastrom Biosciences, Inc.
Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a late-stage development company focused on human cell-based therapies. The AastromReplicell(TM) System - a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells - is the Company's core technology for its Prescription Cell Products (PCP) business and its Cell Production Products (CPP) business. The principal focus of the PCP business is the repair or regeneration of tissue intended for large markets such as bone grafting and severe osteoporosis. The CPP business markets the AastromReplicell(TM) System to researchers and companies for their production of cells for clinical trials. These two businesses are intended to enable Aastrom to generate multiple paths to revenue. The initial commercial phase of the CPP business for dendritic cell production products is underway in Europe and the United States. For more information, visit Aastrom's website at www.aastrom.com.
About Musculoskeletal Transplant Foundation
The Musculoskeletal Transplant Foundation is the country's largest tissue organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A not-for-profit 501(c)3 organization, MTF is a consortium of academic medical institutions and organ procurement and tissue recovery organizations across the country. In 2002, over 275,000 tissue grafts were distributed by MTF, helping over 200,000 patients. For more information, visit MTF's website at www.mtf.org.
This document contains forward-looking statements, including without limitation, statements concerning product development objectives and anticipated results, potential product applications, anticipated market growth and potential advantages of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expected," "intended," "should," "believe," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are clinical trial results, potential product development difficulties, regulatory approval uncertainties, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.
CONTACTS:
Kris M. Maly or Tom Shaffer
Becky Anderson Director of Marketing
Investor Relations Department Musculoskeletal Transplant Foundation
Aastrom Biosciences, Inc. Phone: (800) 946-9008, ext. 2522
Phone: (734) 930-5777
Consolidated Real-time Market Quote*
| Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
| 1.59 | 0.39 (32.50) | N/A | 1.59 (9.51) | 1.599 (10) | 09:59 |
Exchange Quote
| Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
| 1.56 | 0.36 (30.00) | 1.55 (46) | 1.56 (184) | 09:45 |
| Day Volume | Last Size | Open | High | Low |
| 7,254,265 | 600 | 1.61 | 1.75 | 1.30 |
| Latest Ticks | # of Trades | Avg Trade Size | VWAP | 52 Wk High |
| =+== | 2,853 | 2,543 | 1.4979 | 1.32 |
| 52 Wk Low | Prev Close | Avg Day Vol | ||
| 0.22 | 1.20 | 4,080,800 |
Gruß goldhaeschen
Aastrom Biosciences Expands Bone Graft Clinical Trial to Include William Beaumont Hospital in Michigan
ANN ARBOR, Mich., Jan. 6 /PRNewswire-FirstCall/ -- Aastrom Biosciences (Nachrichten) (NasdaqSC: ASTM) announced today that it has expanded the U.S. Phase I/II clinical trial of its adult stem cell-based Tissue Repair Cells (TRCs) in the treatment of severe long bone non-union fractures to include the Department of Orthopedic Surgery at William Beaumont Hospital (Beaumont), located in Royal Oak, MI. This is the third site now engaged in this U.S. multi-center trial, which is already underway at Lutheran General Hospital Chicago, IL, and the University of Michigan Health System, Ann Arbor, MI.
The Principal Investigator for the Beaumont site, Gregory Nowinski, M.D., will be joined by Investigators Patrick Wiater, M.D. and Jeffrey Balazsy, M.D. All of the investigators practice in the Detroit-metro area, and are affiliated with the Department of Orthopedic Surgery at Beaumont, under the direction of Department Chair, Harry Herkowitz, M.D. Accrual of patients into the study is expected to begin immediately.
Aastrom's proprietary TRC bone graft product is also being evaluated in long bone fracture clinical trials in Bochum, Germany and Barcelona, Spain. As a result of positive initial results in the Barcelona study, the Company recently announced plans to expand that trial for these severe fracture indications to accrue additional patients. The TRC product is also in a clinical trial in Barcelona for the treatment of sinus lift bone graft procedures, to generate new bone tissue in the maxillary jaw bone.
"Being a part of these clinical trials allows us to continue working towards finding better treatment options for our patients today and in the future," said Dr. Herkowitz of Beaumont.
About William Beaumont Hospital Department of Orthopedic Surgery
Beaumont's Department of Orthopedic Surgery offers leading edge treatments and technology including minimally invasive surgery, implants and trauma surgery. Beaumont is Michigan's most experienced orthopedic hospital specializing in surgeries of the back, neck, foot, ankle, hand and upper extremities, hip and knee replacement, scoliosis treatment, tumor surgery, pediatric orthopedics and sports medicine. Beaumont has been named among the country's top hospitals for orthopedic care by U.S. News & World Report and Solucient.
Beaumont-Royal Oak, is a 1,061-bed tertiary care, teaching, research and referral center with Level I trauma designation. It ranks first in the United States for outpatient surgeries and second for inpatient surgeries.
About Tissue Repair Cells
Tissue Repair Cells (TRCs) are Aastrom's proprietary mixture of bone marrow stem and progenitor cells produced using patented single-pass perfusion technology in the AastromReplicell(R) System. The clinical procedure begins with the collection of a small sample of bone marrow from the patient's hip in an outpatient setting. TRCs are then produced in the automated AastromReplicell System over a 12-day period. It has been demonstrated in the laboratory that TRCs are able to develop into different types of tissue lineages in response to inductive signals, including blood, bone, cartilage, adipose and vascular tubules. In previous clinical trials, TRCs have been shown to be safe and reliable in regenerating certain normal healthy bone marrow tissues.
About Aastrom Biosciences, Inc.
Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a regenerative medicine company developing treatments for the repair of damaged human tissues and other medical disorders, or the generation of normal human tissues, utilizing the Company's proprietary adult stem cell-based products. Aastrom's strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell(R) System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), several of which are now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.
For more information, visit Aastrom's website at http://www.aastrom.com/.
This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials, product development objectives, potential product applications, and potential advantages of the AastromReplicell(R) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expected," "plans," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are potential patient accrual difficulties, clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.
CONTACTS: Kris M. Maly or Kevin McGrath Becky Anderson Cameron Associates Investor Relations Department Phone: (212) 245-4577 Aastrom Biosciences, Inc. Phone: (734) 930-5777
Aastrom Biosciences, Inc.
Gruß goldhaeschen
Es ist schön, nach Jahren der Entwicklung und Aufmerksamkeit die Erfolge im Depot zu sehen.
Zu GERN und STEM gibt es auch genug Postings.
Gruss E.
Hab ich etwas übersehen oder was für gewichtige Gründe gibt´s dafür ? ? ?
Gruß goldhaeschen
Schönes Wochenende.
Gruss E.
FNWU: Geron ends patent with Advanced Cell Technology and Aastrom Biosciences expands U.S. Phase I/II clinical trial
Jan 07, 2005 (M2 PRESSWIRE via COMTEX) -- Biotechnology industry news provided
by Financial News USA (OTC: FNWU). Geron Corporation (NASDAQ: GERN) announced
that the Board of Patent Appeals and Interferences of the U.S. Patent and
Trademark Office has issued a final judgment ending patent interference number
104,746 between Geron and Advanced Cell Technology Corporation of Worcester,
Mass. Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that it has expanded
the U.S. Phase I/II clinical trial of its adult stem cell-based Tissue Repair
Cells in the treatment of severe long bone non-union fractures to include the
Department of Orthopedic Surgery at William Beaumont Hospital, located in Royal
Oak, MI.
Amgen Inc. (NASDAQ: AMGN) announced that it has established a company-wide South
Asia Tsunami Relief Program and provided an initial cash contribution of $1
million in support of humanitarian aid to the International Federation of Red
Cross and Red Crescent Societies.
BioDefense, Inc. (OTCBB: UBDF) sponsored the Project T2 Technology Transfer
Conference, the nation's leading showcase of new university technologies, hosted
at the Wilshire Grand Hotel in Los Angeles, CA.
About Financial News USA
Financial News USA (OTC: FNWU) is a Next Generation Financial Communications
firm focused on the distribution of market moving news. Our services include but
are not limited to OTCBBWire service, GlobalWire services, Copywriting services
to help you create news worthy press releases, and Investor Relations and
Venture Capital services to assist you if you are looking for more customers or
funding. Our goal is to create a long-term relationship with you and your
company. Financial News USA and its affiliate`s charge each client cash for news
distribution and may take an equity position in the companies mentioned herein,
please visit the disclaimer at www.financialnewsusa.com.
CONTACT: Financial News USA Tel: +1 626 961 8041 e-mail:
info@financialnewsusa.com
M2 Communications Ltd disclaims all liability for information provided within M2
PressWIRE. Data supplied by named party/parties. Further information on M2
PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.
Schaun wir mal, was der Tag bringt !
Bruß goldhaeschen
gruss phill
Angehängte Grafik:
aastrom.png (verkleinert auf 85%)
aastrom.png (verkleinert auf 85%)